Mr. J. David Warren reports

ADAPTOGENICS UPLISTS TO OTCQB VENTURE MARKET

Adaptogenics Health Corp. has been approved to uplist from the OTC Pink market to the OTCQB Venture Market, operated by OTC Markets Group Inc.

The OTCQB, established in 2010, is the premier U.S. marketplace for early-stage and developing companies. Designed to provide improved visibility and greater access to U.S. investors, the OTCQB is recognized by the U.S. Securities and Exchange Commission (SEC) as an established public market.

The uplisting is effective as of Nov. 11, 2026, and the company will continue to trade under the ticker symbol ADPGF in the United States, with its shares also listed on the Canadian Securities Exchange under the symbol ADPT.

The company believes this milestone will support increased liquidity, enhance transparency, and attract a broader base of retail and institutional investors in the U.S. capital markets.

The company has also submitted an application for its common shares to become eligible for electronic clearing and settlement through the Depository Trust Company (DTC). The application is currently under review, and DTC eligibility has not yet been approved. There can be no assurance as to whether or when DTC eligibility will be granted.

J. David Warren, chief executive officer and director of the company, commented: "This uplisting marks an important step in our growth strategy. Trading on the OTCQB Venture Market aligns with our commitment to increasing shareholder value, improving market visibility and maintaining high standards of corporate governance."

About Adaptogenics Health Corp.

Adaptogenics Health is building a science-led company focused on identifying, acquiring, designing and advancing proprietary peptide and small-molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP-1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.

We seek Safe Harbor.